Press coverage about Editas Medicine (NASDAQ:EDIT) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Editas Medicine earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.3359995369337 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Shares of Editas Medicine traded down $1.39, hitting $37.84, during trading hours on Tuesday, Marketbeat Ratings reports. The company had a trading volume of 235,147 shares, compared to its average volume of 1,162,691. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.71 and a current ratio of 11.71. Editas Medicine has a fifty-two week low of $15.28 and a fifty-two week high of $45.02. The firm has a market cap of $1.77 billion, a P/E ratio of -12.70 and a beta of 3.73.
Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Thursday, May 3rd. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.15. Editas Medicine had a negative net margin of 707.98% and a negative return on equity of 58.73%. The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $4.04 million. During the same period in the prior year, the business posted ($0.85) EPS. The business’s revenue for the quarter was up 473.5% compared to the same quarter last year. research analysts predict that Editas Medicine will post -3 EPS for the current fiscal year.
EDIT has been the subject of several analyst reports. BidaskClub cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a research note on Thursday, April 26th. Zacks Investment Research raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Tuesday, May 15th. Chardan Capital dropped their price target on shares of Editas Medicine from $72.50 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, May 15th. Morgan Stanley reissued an “equal weight” rating and issued a $43.00 price target (up previously from $28.00) on shares of Editas Medicine in a research note on Wednesday, March 14th. Finally, ValuEngine raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $46.14.
In other Editas Medicine news, insider Katrine Bosley sold 8,333 shares of the stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $32.16, for a total transaction of $267,989.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew A. F. Hack sold 10,000 shares of the stock in a transaction that occurred on Monday, June 4th. The stock was sold at an average price of $38.63, for a total transaction of $386,300.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,999 shares of company stock worth $1,943,233. Company insiders own 5.20% of the company’s stock.
Editas Medicine Company Profile
Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.